UNSPSC 51373309: Acetaminophen/caffeine/dihydrocodeine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51373309 Acetaminophen/caffeine/dihydrocodeine is a Commodity code, but recent state and local solicitations under this code tag reflect a significant mismatch between the nominal scope and actual procurement activity. The code nominally names a specific pharmaceutical combination product, yet the opportunities posted show state and local governments acquiring naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals with over-the-counter products through cooperative purchasing vehicles. The work being solicited is pharmaceutical procurement at scale — including manufacturer relationships, wholesaler-mediated distribution, compliance with cGMP and Drug Supply Chain Security Act requirements, and pricing models negotiated across state and local health systems and pharmacy benefit programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon). The code shows little activity directly tied to acetaminophen/caffeine/dihydrocodeine formulations specifically.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County's IFB 60459723LAS, posted June 30, 2026, with response due July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, exploring vendor capacity for direct-to-manufacturer prescription contracting outside traditional PBM and wholesaler channels; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802, posted January 20, 2026, with response due March 26, 2026, establishing multi-award contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson. The MMCAP solicitation specifies 3 percent administrative fees, $5 million commercial general liability insurance, and performance penalties of $200 to $1,500 per violation. The code's recent activity reflects pharmaceutical distribution infrastructure and procurement rather than procurement of the specific formulation the code nominally describes.